BRAF and non-small cell lung carcinoma: According to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) NSCLC version 5.2021, patients with aNSCLC who harbor ALK, ROS1, or RET rearrangements, EGFR, MET, BRAF, or KRAS mutations, NTRK fusions, and/or a high programmed death‐ligand 1 (PD‐L1) level should have US Food and Drug Administration (FDA)‐approved targeted treatment.5